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ABSTRACT
INTRODUCTION: Memantine has been suggested as a migraine prophylaxis therapy in some observational studies.
OBJECTIVE: To determine the mean change in MIDAS score after Memantine in patients having migraine.
SAMPLING TECHNIQUE: Non-probability, consecutive sampling.
Methods: This study was conducted in the Neurology department, Bolan Medical Complex Hospital, Quetta. January
2017 to January 2018. All patients in the outpatient department of Bolan medical complex hospital, Quetta, with the
diagnosis of migraine were enrolled in the current study after informed consent.
RESULTS: A total of 68 patients with a mean age of 32.32 ± 8.44years were enrolled in the study. Gender distribution
of the patients showed that most of the patients were female. Most of the patients had a duration of symptoms of
>3± 2.11 years. Before starting treatment, the mean MIDAS score was age group 18-30 years 43.53 ± 13.36 and
at the end of treatment was 9.86 ± 6.28 (P=0.005). 31-45 years age group before MIDAS score was 43.73 ± 8.83
and treatment after MIDAS score 9.31±3.36. The difference in MIDAS scores before and after treatment was
assessed.
CONCLUSION: The current small cohort has been effective in predicting that the use of Memantine may lead to the
improvement in MIDAS score regarding the management of Migraines; however, large-scale studies are needed to
validate this current study's results further.
KEYWORDS: Migraine; Memantine; Headache; MIDAS

INTRODUCTION
Migraine is the second most common brain disorder (1).
According to a report by World Health Organization,
migraine is ranked as 19th among all diseases causing
disability(1). Migraine and other benign recurrent
headache disorders are major public health problems.
They are associated with substantial personal suffering,
disability, and societal expense (2).Moreover, Migraine is
a common disease, and various therapeutic options are
currently available(2). The most commonly used
treatments for migraines include triptans, analgesics
like NSAIDS, ergot derivatives, and antiemetics.
However, the recent advances have raised the bar and
options. Ubrogepant, which is an oral calcitonin
gene-related peptide (CGRP) receptor antagonist and
monoclonal antibiotic receptor antagonist, has been
showing significant improvement in symptoms in recent
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trials (3, 4). Additionally, the Memantine had been
recently introduced for the treatment of migraines (5). It
is
an
uncompetitive
antagonist
of
N-methyl-D-aspartate (NMDA) receptors, approved in
the USA and many countries worldwide to treat
migraines (5). It is currently administered twice daily as
an immediate-release formulation, with a maximum
recommended 20 mg/day (6). Khalid S et al. conducted
a study which described that after treatment of
migraine for 3 months by Memantine, the mean
Migraine Disability Assessment Scale (MIDAS) score
was found to be 6.72 ± 6.41 vs. 39.52 ± 21.27,
which was noted before starting the treatment (P=
0.00) (7). As Memantine is a relatively newer drug and
only a few studies are available in the literature
regarding the role of Memantine for migraine

26

V O L . 1 6 ( 1 ) J A N U A R Y- M A R C H 2 0 2 1

O R I G I N A L

A R T I C L E

Outcomes:
Within the age group of 18-30 years, the MIDAS score
before the start of treatment was 43.53 ± 13.36, and
at the end of treatment was 9.86 ± 6.28 (P=0.00).
For the age group 31-45 years, the MIDAS score before
the treatment started was 43.73 ± 8.83, and after the
treatment, the MIDAS score was 9.31±3.36. The
difference in MIDAS score before and after treatment
was assessed, and it was stratified for age, gender, and
duration of symptoms. All results are summarized in
Table 4.

management (8). Recently published studies have
emphasized the role of Memantine for migraines with
promising results (7-9). The current study aims to observe
the effects of Memantine on migraine management in
a tertiary care hospital.
MATERIAL AND METHODS
After authorization from the institutional ethical board,
all outpatient general neurology clinic patients
diagnosed with Migraine were enrolled in the research
study, and written consent was obtained. The inclusion
criteria included patients with the diagnosis of
migraine, patients with age groups 18-45. Exclusion
criteria included patients already taking Memantine,
patients
with
known
psychiatric
disorders,
anti-depressants, and analgesics. Patients were
assured regarding confidentiality for an anticipated
better outcome. Patients fulfilling the inclusion criteria
having migraines were assessed and were asked to fill
MIDAS score (7-10). After that, Memantine was started as
5mg for the 1st week, 10mg for the 2nd week, 15mg
for the 3rd week, and 20mg for the 4th week. They
were maintained at a dose of 20mg till the end of 3
months. All these patients were asked to maintain a
headache diary. At the end of 3-months of treatment,
they were asked for a MIDAS score again. The collected
data, including age, gender, and duration of symptoms,
were entered and analyzed accordingly using SPSS
version 20 through its statistical program. Mean and
standard deviation was calculated for quantitative
variables like age, age at the time of diagnosis of
migraine, and MIDAS score. Frequencies and
percentages were calculated for qualitative variables
like gender. Mean MIDAS score was calculated both
before and end of the treatments, and student t-test
was applied for comparison. Effect modifiers like age,
gender, and duration since treatment were addressed
through stratification using an independent sample
t-test. P-value <0.05 was considered significant.

TABLE No. 1 Age DISTRIBUTION (N=68)
Age groups

No. of patients

%

18-30 Years

30

43.7%

31-45 Years

38

55.7%

Total

68

100

Mean ± SD

32.3 ± 8.4years

Abbreviations: N= Number; SD= Standard deviation
TABLE No. 2 GENDER DISTRIBUTION (n=68)
Gender

No. of patients

%age

Male

26

38.2%

Female

42

61.8%

Total

68

100

Abbreviations: N= Number
TABLE No. 3 Distribution of patients according to
duration of symptoms (N=68)
Duration of symptoms

No. of patients

%

<3 years

23

33.7%

>3 years

45

66.3%

Total

34

100

Mean+SD

4.4 ± 2.1 years

Results
Demographic:
A total of 68 patients were included in the study. The
mean age of the patients was found to be 32.3 ± 8.3
years. Patients were further categorized according to
age groups into 2 groups (18-30 years and 31-45
years). (Table 1) Most of the patient were female
61.8% (N= 42) compared to male 38.2% (N= 26).
(Table 2) Most of the patients in the current study had
a duration of symptoms of >3 years were 45 (66.3%),
with the mean duration of symptoms in the overall
cohort was found as 4.4 ± 2.1 years (Table 3).
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Difference in MIDAS score according to age
groups, gender and duration of symptoms
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18-30 Years

43.53 ± 13.36

9.86 ± 6.28

0.00

31-45 Years
Gender

43.73 ± 8.83

9.31 ± 3.36

0.00

Male

50.96 ± 7.72

9.92 ± 4.85

0.00

Female

38.83 ± 9.81

9.28 ± 4.77

0.00

and its onset of action was brief (only 3 days) as
compared to longer periods with other migraine
prophylaxis agents. Additionally, being a category B risk
for pregnancy it may be suitable for pregnant migraine
sufferers. Our study has several limitations including
sample size , lack of randomization and unblinded
outcome assessment. Despite these limitations this is
first study to our knowledge in Pakistan. Larger,
randomized controlled studies are required to prove
efficacy of this treatment in refractory migraine
patients.
Conclusion

MIDAS score before
treatment

MIDAS score after
treatment

P-Value

Age groups

Duration since symptoms
<3 years

49.00 ± 9.33

11.33 ± 4.83

0.00

>3 years

40.72 ± 10.72

8.59 ± 4.60

0.00

In our small cohort study, the Memantine has shown an
excellent improvement in MIDAS score regarding the
management of Migraine; however, the current study
results need to be explored further with well-powered
study and randomized control trials.

Discussion
Migraine is associated with economic burden, disability
and poor quality of life. Despite these challenges
majority of patients avoid or delay taking medications
due to side effects and cost. (8-10) There are many
options available for migraine prophylaxis with emerging
data related to glutamate modulators. (11) Increased
levels of glutamate in CSF of migraine patients suggest
a pathophysiological link. Few open label studies have
suggested Memantine (Glutamate N Methyl aspartate
receptor antagonist) may be useful in migraine
patients. (12-16) In one open label study of 60 patients
more than half of patients showed 50% reduction in
migraine pain frequency.(9) These studies are limited
being non-randomized, unblinded with varying eligibility
criteria and outcome measures. Use of valproate is
associated with substantial side effects especially
among women (13-14). Topiramate and venlafaxine are
also associated with many limiting side effects
especially among young migraine patients. In our study,
Memantine was associated with minimal side effects
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